ISSCR News


Remembering Connie Eaves
Announcements Kym Kilbourne Announcements Kym Kilbourne

Remembering Connie Eaves

The ISSCR is deeply saddened to learn of the passing of Connie Eaves, a tremendous friend and globally renowned stem cell scientist. Dr. Eaves was a member of the Stem Cell Reports Editorial Board and served on the ISSCR Board of Directors from 2009-2015. Many current and former ISSCR leaders fondly remember Dr. Eaves and her impactful contributions to the Society and stem cell community.

Read More
New Podcast Episode. Climbing the Scientific Mountain of Retinal Regeneration
Announcements Megan Koch Announcements Megan Koch

New Podcast Episode. Climbing the Scientific Mountain of Retinal Regeneration

Collectively, retinal degenerative disorders are a major cause of blindness worldwide. For example, one of the most common disorders is age related macular degeneration, which alone affects nearly 200 million globally. In humans, and other mammals, the loss of the retinal cells is an irreversible process. However, in some non-mammalian vertebrates like frogs and fish, retinal neurons can regenerate. This process is dependent upon Müller glia, which can re-enter the cell cycle and reprogram into neurogenic progenitors upon retinal injury or disease. Progress has been made in understanding the genetic program underlying these regenerative process, and proof-of-principle experiments in the adult mouse retina demonstrated that genetic programs in frog and fish can be coopted to induce neurogenesis in mammals. Our guests today have extended this research to genetically reprogram fetal or organoid-derived human Müller glia into retinal neurons. They will talk about this work, the background underlying it and its potential applications.

Read More
The ISSCR Provides Comments on FDA’s Draft Guidance for Potency Assurance for Cellular and Gene Therapy Products 
Announcements, Policy Kym Kilbourne Announcements, Policy Kym Kilbourne

The ISSCR Provides Comments on FDA’s Draft Guidance for Potency Assurance for Cellular and Gene Therapy Products 

On 5 March 2023, the ISSCR submitted comments on the Food and Drug Administration’s draft guidance for Potency Assurance for Cellular and Gene Therapy (CGT) Products. ISSCR appreciates FDA’s commitment to assuring the potency of human CGT products at all stages of the product lifecycle. This guidance from the FDA will help our members, who are at the forefront of research and innovation, in their work.

Read More

Receive ISSCR Press Releases

Sign up be a part of ISSCR’s media list. Media Contact: Kym Kilbourne, Director of Media and Strategic Communications

Subscribe to ISSCR News.

Each month, ISSCR delivers scientific, policy, and community to your inbox .